Compare Stocks → Crypto Market Preps For Trillions Worth of Inflows! (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBIONASDAQ:PBLANASDAQ:RGLSNASDAQ:SGYP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCatalyst Biosciences$0.77$0.19▼$8.69$291.29M1.05763,526 shs32,246 shsPBLAPanbela Therapeutics$0.67+4.7%$1.53$0.41▼$477.00$2.23M1.54276,409 shs99,445 shsRGLSRegulus Therapeutics$2.88+1.1%$1.68$0.77▼$3.79$57.53M1.459.22 million shs886,367 shsSGYPSynergy Pharmaceuticals$0.02$0.03▼$2.23$7.44M4.946.08 million shsN/AThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCatalyst Biosciences0.00%0.00%0.00%0.00%+3,936.58%PBLAPanbela Therapeutics+5.44%+0.92%-41.32%-96.56%-99.77%RGLSRegulus Therapeutics+1.23%+15.20%+102.82%+128.57%+246.78%SGYPSynergy Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCatalyst BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APBLAPanbela Therapeutics1.2199 of 5 stars3.53.00.00.00.90.00.6RGLSRegulus Therapeutics3.0469 of 5 stars4.42.00.00.03.12.50.0SGYPSynergy PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCatalyst BiosciencesN/AN/AN/AN/APBLAPanbela Therapeutics3.00Buy$500.0073,996.03% UpsideRGLSRegulus Therapeutics2.80Moderate Buy$7.25151.74% UpsideSGYPSynergy PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest SGYP, CBIO, RGLS, and PBLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024PBLAPanbela TherapeuticsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/25/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/19/2024RGLSRegulus TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $11.003/18/2024RGLSRegulus TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/18/2024RGLSRegulus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.003/18/2024RGLSRegulus TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$6.003/13/2024RGLSRegulus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$2.00 ➝ $3.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCatalyst Biosciences$790K0.00N/AN/A($0.78) per share0.00PBLAPanbela TherapeuticsN/AN/AN/AN/A($4,607.33) per shareN/ARGLSRegulus TherapeuticsN/AN/AN/AN/A$1.05 per shareN/ASGYPSynergy Pharmaceuticals$16.82M0.00N/AN/A($0.02) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCatalyst Biosciences-$8.24M-$1.38N/AN/AN/AN/A-364.68%-281.68%4/4/2024 (Estimated)PBLAPanbela Therapeutics-$34.93M-$669.09N/AN/AN/AN/A-1,561.81%-162.49%5/2/2024 (Estimated)RGLSRegulus Therapeutics-$30.04M-$1.59N/AN/AN/AN/A-109.21%-80.55%5/9/2024 (Estimated)SGYPSynergy Pharmaceuticals-$224.33M-$1.02N/AN/AN/A-332.11%N/A-118.14%N/ALatest SGYP, CBIO, RGLS, and PBLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2024Q4 2023PBLAPanbela Therapeutics-$24.34-$65.90-$41.56-$65.90N/AN/A3/21/2024Q4 2023RGLSRegulus Therapeutics-$0.40-$0.40N/A-$0.40N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCatalyst BiosciencesN/AN/AN/AN/AN/APBLAPanbela TherapeuticsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/ASGYPSynergy PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCatalyst BiosciencesN/A2.882.88PBLAPanbela Therapeutics0.870.210.21RGLSRegulus TherapeuticsN/A3.313.31SGYPSynergy PharmaceuticalsN/A0.520.38OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCatalyst Biosciences5.98%PBLAPanbela Therapeutics4.37%RGLSRegulus Therapeutics92.38%SGYPSynergy Pharmaceuticals28.47%Insider OwnershipCompanyInsider OwnershipCBIOCatalyst Biosciences2.92%PBLAPanbela Therapeutics0.11%RGLSRegulus Therapeutics8.41%SGYPSynergy Pharmaceuticals4.80%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCatalyst Biosciences737.98 million36.87 millionOptionablePBLAPanbela Therapeutics63.48 million3.48 millionNot OptionableRGLSRegulus Therapeutics3020.22 million18.52 millionOptionableSGYPSynergy PharmaceuticalsN/A248.04 millionN/AOptionableSGYP, CBIO, RGLS, and PBLA HeadlinesSourceHeadlineSynergy starts construction on one of Australia’s biggest batteriespower-technology.com - March 19 at 6:16 AMPYC Therapeutics and Google Cloud partner for new precision medicinesmsn.com - January 2 at 12:00 PMSynergy Pharma Investors Win Revival of Suit Over Stock Dilutionnews.bloomberglaw.com - August 28 at 3:37 PMAvia Solutions Group acquires UK airline Synergy Aviationstattimes.com - July 17 at 8:57 AMDental Association Calls for Synergy Between Public, Private Practicesthisdaylive.com - June 15 at 9:15 AMSynergy Pharmaceuticals Inc Unit (SGYPU)investing.com - May 9 at 5:36 PMMarket Factor Synergy Signals Exciting Growth For Digital Pathologyforbes.com - April 12 at 9:54 AMHPCL signs pact with BPCL for hydrogen synergyauto.economictimes.indiatimes.com - April 4 at 9:37 AMDifferent resistorsbbc.co.uk - March 29 at 4:27 PMMains cablesbbc.co.uk - March 28 at 6:37 PMEnergy changes in brakingbbc.co.uk - March 28 at 6:37 PMBlues plans launch Synergie to cut costs for the priciest drugsmodernhealthcare.com - January 8 at 12:45 AMSynergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson Investmentthestreet.com - December 18 at 5:49 PMJiangxi Synergy Pharmaceutical Co Ltd (300636)investing.com - September 13 at 12:21 AMi-Synergy’s Ledger Labs provides software development in blockchain and AI to businessstockhead.com.au - July 25 at 11:44 PMSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call Transcriptseekingalpha.com - May 16 at 5:10 PMHere's a Reason Why Synergy Pharma (SGYP) Stock Is Rallying Todaythestreet.com - January 18 at 8:36 PMOKYO Pharma LTD: OKYO Pharma Limited: Directorate Changefinanznachrichten.de - December 2 at 6:56 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCatalyst BiosciencesNASDAQ:CBIOCatalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.Panbela TherapeuticsNASDAQ:PBLAPanbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, develops disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; FlynpoviTM, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase. It has a research agreement with the Johns Hopkins University School of Medicine for the development of Panbela's investigative agent ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.Regulus TherapeuticsNASDAQ:RGLSRegulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Synergy PharmaceuticalsNASDAQ:SGYPSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.